Veterinary Medicines

BRAVOXIN 10 BG

Suspended
  • Clostridium perfringens, type A, alpha toxoid
  • Clostridium perfringens, type B and C, beta toxoid
  • Clostridium perfringens, type D, epsilon toxoid
  • Clostridium novyi, toxoid
  • Clostridium septicum, toxoid
  • Clostridium tetani, toxoid
  • Clostridium sordellii, toxoid
  • Clostridium haemolyticum, toxoid
Download as PDF

Product identification

Medicine name:
БРАВОКСИН 10 БГ
BRAVOXIN 10 BG
Active substance:
  • Clostridium perfringens, type A, alpha toxoid
  • Clostridium perfringens, type B and C, beta toxoid
  • Clostridium perfringens, type D, epsilon toxoid
  • Clostridium novyi, toxoid
  • Clostridium septicum, toxoid
  • Clostridium tetani, toxoid
  • Clostridium sordellii, toxoid
  • Clostridium haemolyticum, toxoid
Target species:
  • Sheep
  • Cattle
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Clostridium perfringens, type A, alpha toxoid
    0.50
    international unit(s)
    /
    1.00
    Dose
  • Clostridium perfringens, type B and C, beta toxoid
    18.20
    international unit(s)
    /
    1.00
    Dose
  • Clostridium perfringens, type D, epsilon toxoid
    5.30
    international unit(s)
    /
    1.00
    Dose
  • Clostridium novyi, toxoid
    3.80
    international unit(s)
    /
    1.00
    Dose
  • Clostridium septicum, toxoid
    4.60
    international unit(s)
    /
    1.00
    Dose
  • Clostridium tetani, toxoid
    4.90
    international unit(s)
    /
    1.00
    Dose
  • Clostridium sordellii, toxoid
    4.40
    international unit(s)
    /
    1.00
    Dose
  • Clostridium haemolyticum, toxoid
    11.70
    international unit(s)
    /
    1.00
    Dose
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Sheep
    • Cattle
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Suspended
Authorised in:
  • Bulgaria
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • INTERVET INTERNATIONAL B.V.
Responsible authority:
  • BFSA
Authorisation number:
  • 0022-1719
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Bulgarian (PDF)
Published on: 1/06/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."